iPierian

Careers Contact

  • Company
    • About Us
    • People
      • Scientific Founders
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Key Advisors
    • Investors
    • Careers
      • Open Positions
    • Contact
  • Technology
    • Technology Overview
    • iPS Cell Technology
    • Differentiation
      • Proof of Concept
      • Advancing Cellular Programming
      • Scientific Advantages
    • Phenotypic Assay Development
  • Therapeutic Areas
    • Therapeutic Areas Overview
    • Neurological Diseases
    • Cardiovascular Disease
    • Metabolic Diseases
  • Collaborators
    • Collaborators Overview
  • News & Events
    • Newsroom
    • In the News
    • Press Releases
      • 2010
      • 2009
      • 2008
    • Media Kit
    • Events
  • Newsroom
  • In the News
  • Press Releases
    • 2010
    • 2009
    • 2008
  • Media Kit
  • Events
"We are dedicated to making iPSC technology the industry standard for the early introduction of human pharmacology into the drug discovery process."
-Michael C. Venuti, Ph.D., CEO, iPierian

 

Quote Border

2009

Print
Email

10/21/09
iPierian To Collaborate with Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant

 

09/01/09
iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer

 

08/06/09
iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board

 

07/08/09
iZumi Bio and Pierian Merge to form iPierian to Advance Cellular Reprogramming

 

06/11/09
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

 

05/06/09
iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development

 

04/14/09
iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology

 

02/12/09
iZumi Bio. Inc., Appoints John Walker as Chief Executive Officer

 

© 2009 iPierian Inc. All rights reserved.

Home Site Map